Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

Wegovy, the brand name for semaglutide, is only available as a weight-loss drug for people who are severely obese and living ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the ...

By considering the Debt-to-Equity ratio, Eli Lilly can be compared to its top 4 peers, leading to the following observations: Eli Lilly is positioned in the middle in terms of the debt-to-equity ...

Eli Lilly's (NYSE: LLY) stock is up by more than 736% over the last five years, largely thanks to its best-selling medicines for type 2 diabetes and obesity. And while it likely has plenty of ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...